ストックスクリーナーアプリを入手
26.59
3.79%
0.97
前日終値:
$25.62
開ける：
$25.86
24時間の取引高:
620.07K
Relative Volume:
0.48
時価総額：
$2.03B
収益：
-
当期純損益:
$-64.16M
株価収益率:
-20.93
EPS:
-1.2702
ネットキャッシュフロー:
$-69.06M
1週間 パフォーマンス:
+4.52%
1か月 パフォーマンス:
-8.47%
6か月 パフォーマンス:
-25.66%
1年 パフォーマンス:
-18.39%
1日の値動き範囲:
$25.47
$26.95
1週間の範囲:
$24.79
$26.95
52週間の値動き範囲:
$14.80
$40.47
Cg Oncology Inc Stock (CGON) Company Profile
CGON を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
26.59 | 1.95B | 0 | -64.16M | -69.06M | -1.2702 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-02 | 開始されました | JP Morgan | Overweight |
| 2025-04-16 | 開始されました | Scotiabank | Sector Perform |
| 2025-01-07 | 開始されました | TD Cowen | Buy |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-09-23 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-28 | 開始されました | ROTH MKM | Buy |
| 2024-06-28 | 開始されました | BofA Securities | Buy |
| 2024-02-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-02-20 | 開始されました | Goldman | Neutral |
| 2024-02-20 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-14 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Cg Oncology Inc (CGON) 最新ニュース
Promising Market Position and Investment Opportunity: CG Oncology’s Creto in NMIBC Treatment - TipRanks
CG Oncology, Inc. (NASDAQ:CGON) Position Reduced by Nuveen Asset Management LLC - Defense World
BNP Paribas Financial Markets Lowers Stake in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
CG Oncology’s SWOT analysis: bladder cancer treatment stock shows promise amid competition - Investing.com
Bank of America Corp DE Has $6.01 Million Stake in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Millennium Management LLC Invests $7.14 Million in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,026 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success - MSN
Deutsche Bank AG Acquires 13,589 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology (NASDAQ:CGON) Given New $52.00 Price Target at Morgan Stanley - Defense World
CGON Stock Rating Maintained by Morgan Stanley Despite Price Target Cut | CGON Stock News - GuruFocus
Cantor Fitzgerald Lowers Earnings Estimates for CG Oncology - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Position Boosted by Northern Trust Corp - Defense World
Q2 Earnings Forecast for CG Oncology Issued By HC Wainwright - Defense World
CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference - The Manila Times
Leading Bladder Cancer Drug Developer CG Oncology Takes Stage at Major RBC Healthcare Conference - Stock Titan
CG Oncology (NASDAQ:CGON) Shares Gap Down on Disappointing Earnings - Defense World
Decoding CG Oncology Inc (CGON): A Strategic SWOT Insight - GuruFocus
CG Oncology reports Q1 EPS (45c), consensus (37c) - TipRanks
CGON Q1 Revenue Falls Short; Advances in Bladder Cancer Therapy - GuruFocus
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - ADVFN
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
CG Oncology Q1 Loss Widens, Revenue Falls - marketscreener.com
CG Oncology, Inc. SEC 10-Q Report - TradingView
CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Here Are Reasons Why Cg Oncology Inc (NASDAQ: CGON) Is A Great Choice Now - Stocksregister
CG Oncology Jumps 25% on Positive Trial Results - Orange County Business Journal
CG Oncology (NASDAQ:CGON) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Recommendation of “Buy” by Analysts - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by Invesco Ltd. - Defense World
CG Oncology initiated with an Overweight at JPMorgan - TipRanks
CGON Stock: JP Morgan Initiates Coverage with Overweight Rating - GuruFocus
JPMorgan Initiates Coverage on CG Oncology With Overweight Rating, $41 Price Target - marketscreener.com
CGON: JPMorgan Starts Coverage with Overweight Rating and $41 Ta - GuruFocus
CG Oncology (NASDAQ:CGON) Reaches New 1-Year Low After Insider Selling - Defense World
CGON: JPMorgan Starts Coverage with Overweight Rating and $41 Target | CGON Stock News - GuruFocus
Why CG Oncology, Inc. (CGON) Surged on Monday - MSN
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Cg Oncology Inc’s (CGON) Stock Is Harder To Predict Than You Think - Stocksregister
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Wells Fargo & Company MN - Defense World
A look into Cg Oncology Inc (CGON)’s deeper side - Sete News
Stock Performance Spotlight: Cg Oncology Inc (CGON) Ends the Day at 26.94, Down by -3.68 - DWinneX
Could Cg Oncology Inc (NASDAQ: CGON) Be The Biggest Winner? - Marketing Sentinel
Barclays PLC Acquires 10,737 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology's Bladder Cancer Drug Impresses InvestorsHere's Why - AOL.com
Cg Oncology Inc [CGON] Stock sold by Insider POST LEONARD E for $28000.0 - knoxdaily.com
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? - MSN
TD Cowen Sticks to Its Buy Rating for CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (NASDAQ:CGON) Given Overweight Rating at Cantor Fitzgerald - Defense World
Cg Oncology Inc (CGON) 財務データ
収益
当期純利益
現金流量
EPS
6.48%
大文字化:
|
ボリューム (24 時間):